Hopkins Researchers Discover Genetic Pathway Linked To 90 Percent Of Colon Cancer

March 21, 1997

Researchers at the Johns Hopkins Oncology Center and University Hospital in Utrecht, the Netherlands have identified a genetic pathway that may play a role in the development of as many as 90 percent of all colon cancers. They say that the abnormal gene activity in this pathway could offer new targets for anticancer drug therapy. Their findings are reported in two collaborative papers in the March 21, 1997, issue of Science.

The pathway is associated with a tumor suppressor gene called APC, identified by the Hopkins team in 1991 and found to be mutated in 85 percent of all colon cancers. In the new studies, the teams found that the mutation of APC results in the overactivation of two other genes called B-catenin, previously associated with APC by Hopkins researchers, and Tcf, recently isolated by the Netherlands researchers.

"These three genes are part of a pathway--an interconnected series of genes that communicate with one another through the production of proteins to regulate the growth and death of cells," says Kenneth Kinzler, Ph.D., associate professor of oncology at the Hopkins Oncology Center and co-investigator in these studies. "APC is actually a negative control mechanism, or "off switch," for B-catenin and Tcf. When the APC gene is mutated, it cannot perform this function," he says. "Without APC to regulate them, proteins produced by the B-catenin and Tcf genes continue to signal cells to grow, but not to die. This alteration of the cell cycle eventually results in colon cancer."

"In most colon cancers, the pathway is overactive due to APC mutation, and cells never receive the signal to die," says Patrice J. Morin, Ph.D., of the Howard Hughes Medical Institute at the Johns Hopkins Oncology Center and lead author of this study. "In colon cancers that do not have APC mutations, we found a significant number of B-catenin gene mutations, which appear to result in similar overactivation of the pathway."

Kinzler and his colleagues believe the malfunctioning pathway could be corrected with drugs known as "inhibitors" that block B-catenin and Tcf gene function--the role the APC gene normally plays. "It is much easier to block the function of B-catenin and Tcf than to try to restore the missing function of APC. This is what makes the discovery of this pathway so exciting. Not only do we understand what is happening, but we may actually be able to do something about it," says Kinzler.

Kinzler believes this same approach also may be beneficial to people diagnosed with an inherited genetic disease known as Familial Adenomatous Polyposis (FAP). This condition is characterized by the formation of hundreds to thousands of polyps in the colon, some of which eventually become cancerous. Several years ago, the Hopkins researchers linked the development of FAP to mutations of the APC gene.

Approximately 131,000 new cases of colon cancer will be diagnosed in the United States this year, and approximately 37,000 people will die from the disease. Colon cancer is the third most common cancer diagnosed in both men and women.

In addition to Kinzler and Morin, other participants in this research include Bert Vogelstein, M.D., of the Howard Hughes Medical Institute at the Johns Hopkins Oncology Center; Andrew B. Sparks, Ph.D., of the Johns Hopkins Oncology Center; and Hans Clevers, M.D., Ph.D., Vladimir Korinek, and Nick Barker, M.D., from University Hospital in the Netherlands.
-end-


Johns Hopkins Medicine

Related Colon Cancer Articles from Brightsurf:

New prognostic markers for colon cancer identified
The study recently published by MedUni Vienna and collaborative partners nominates ILSs as novel prognostic players orchestrating the pathobiology of metastatic colorectal cancer.

Turning colon cancer cells around
Using a modified natural substance along with current approaches could improve colon cancer treatment, according to findings by University of California, Irvine biologists.

Uncovering the pathway to colon cancer
The hidden world of genetic changes, or mutations, in healthy colon tissue has been uncovered by scientists at the Wellcome Sanger Institute and their collaborators.

Colon cancer growth reduced by exercise
Exercise may play a role in reducing the growth of colon cancer cells according to new research published in The Journal of Physiology.

Towards a better understanding of how colon cancer develops and progresses
Researchers from the University of Luxembourg have discovered a molecular mechanism that is responsible for the spread of cancer cells in the body and the development of metastases in patients with colon cancer.

New target protein for colon cancer identified
Researchers at Boston University School of Medicine (BUSM) have identified a new potential target protein (c-Cbl) they believe can help further the understanding of colon cancer and ultimately survival of patients with the disease.

Colon cancer -- Targeting tumor cell plasticity
Cell type switch helps colon cancer evade treatment, a study suggests.

A bacterial duo linked to colon cancer
Scientists have identified a combination of bacteria that appears to increase the risk of colon cancer.

New model could speed up colon cancer research
Using the CRISPR gene editing system, MIT researchers have shown they can generate colon tumors in mice that very closely resemble human colon tumors, an advance that should allow scientists to learn more about how the disease progresses and also help them test potential new drugs.

Are dialysis patients being over-screened for colon cancer?
Colonoscopies are being performed more often on healthier dialysis patients than on those with more limited life expectancies; however, overall, dialysis patients are being screened at a much higher rate relative to their life expectancy than their counterparts without kidney failure.

Read More: Colon Cancer News and Colon Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.